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FGF-23 in patients with end-stage renal disease on hemodialy-
sis.
Background. Fibroblast growth factor (FGF)-23 is a recently
identified circulating factor which causes renal phosphate wast-
ing disorders. Although the mechanism of regulation of FGF-23
secretion is unknown, plasma FGF-23 level may be regulated
or affected by serum phosphate levels because of its hypophos-
phatemic effect.
Methods. We tested the hypothesis that plasma FGF-23 levels
may be increased in hyperphosphatemia in patients with end-
stage renal disease (ESRD) on maintenance hemodialysis. We
measured plasma FGF-23 levels in 158 male uremic patients
on maintenance hemodialysis. Plasma samples were obtained
before starting dialysis sessions to determine FGF-23 levels by
enzyme-linked immunosorbent assay (ELISA).
Results. Plasma FGF-23 level exhibited significant and pos-
itive correlations with inorganic phosphate, intact parathyroid
hormone (PTH), corrected calcium, and duration of hemodial-
ysis on simple regression analyses. All these associations re-
mained significant in multiple regression analyses.
Conclusion. Serum phosphate, calcium, and intact PTH could
be regulators of FGF-23 levels in uremic patients on mainte-
nance hemodialysis. Our results may provide new insights into
the pathophysiologic effects of FGF-23 on calcium-phosphate
homeostasis.
Oncogenic osteomalacia, X-linked hypophos-
phatemia, and autosomal-dominant hypophosphatemic
rickets are similar disorders characterized by hypophos-
phatemia accompanied by increased renal phosphate
wasting [1, 2]. Recently, autosomal-dominant hypophos-
phatemic rickets has been reported to be associated
with mutations of a member of the fibroblast growth
factor (FGF) family, FGF-23 [3], missense mutations of
Key words: FGF-23, phosphate, PTH, calcium, renal failure, hemodial-
ysis.
Received for publication January 18, 2003
and in revised form September 3, 2003, and November 27, 2003
Accepted for publication December 22, 2003
C© 2004 by the International Society of Nephrology
which identified in families with autosomal-dominant hy-
pophosphatemic rickets prevent cleavage of FGF-23 [4].
FGF-23 has been demonstrated to be a secreted protein
that is overexpressed in tumors causing hypophos-
phatemia in patients with oncogenic osteomalacia [5,
6]. Although FGF-23 appears to be expressed in a few
tissues under normal conditions [3], the manner of
regulation of its secretion is still unknown. In this study,
we attempted to determine the parameters that regulate
FGF-23 levels in patients on maintenance hemodialysis,
who have phosphate retention.
METHODS
Patients
This study included 158 male patients with end-
stage renal disease (ESRD) treated with maintenance
hemodialysis who gave written informed consent. This
study was approved by the Institutional Ethics Commit-
tee (Osaka City University Graduate School of Medicine
Approval No. 291). The patients received 3 to 5 hours
of hemodialysis, three times a week, using bicarbonate
dialysate. Dialyzer membranes were cellulose triacetate
(45%), modified cellulose (20%), polysulfone (15%),
polymethylmethacrylate (15%), and others (5%). The av-
erage ± SD of age and duration of hemodialysis of the
subjects were 61.9 ± 0.9 years old and 6.6 ± 0.2 years.
The underlying renal diseases were diabetic nephropa-
thy (44%), chronic glomerulonephritis (29%), hyperten-
sive nephrosclerosis (8%), polycystic disease (4%), lupus
nephritis (1%), chronic pyelonephritis (1%), and others
or unknown (13%). Forty six healthy volunteers and 30
nondialyzed uremic patients (serum creatinine, median
6.2 mg/dL; range 1.5 to 15.3), who gave written informed
consent, were also employed in this study.
Measurement of plasma FGF-23 concentration
Blood samples were obtained just before starting
hemodialysis sessions as previously described. The blood
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was quickly mixed with 5 mg of edetic acid and then
plasma was separated by centrifugation. Plasma sam-
ples were stored at −20◦C until assayed. Plasma FGF-23
concentrations were measured using the Human FGF-23
enzyme-linked immunosorbent assay (ELISA) Kit (Im-
mutopics, Inc., San Clemente, CA, USA) according to
the manufacturer’s instruction. Serum samples were also
collected at the same time to measure other parameters.
Stastical analysis
Results were summarized as mean ± standard error
(SE). Serum calcium levels were adjusted for serum albu-
min and expressed as corrected calcium. Correlations be-
tween two variables were examined by linear regression
analysis. Independent associations between variables
were evaluated by multiple regression analysis. Because
intact parathyroid hormone (PTH) and FGF-23 exhib-
ited skewed distributions, log-transformed values were
used to fit linear models. P values less than 0.05 were
taken as statistically significant. All analyses were per-
formed using commercially available software for Win-
dows (StatView 5) (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Plasma levels in patients on maintenance hemodialysis
FGF-23 levels of the patients on maintenance
hemodialysis (median 4715 RU/mL, range 150 to 115,000)
were significantly above the reference range (median 76.5
RU/mL, range 17.8 to 197.0) derived from 46 healthy
volunteers (P < 0.0001, Mann-Whitney U test). The lev-
els of plasma FGF-23 (median 188.0 RU/mL, range 63.6
to 5592.0) in 30 nondialyzed uremic patients were sig-
nificantly higher than those of healthy volunteers (P <
0.0001, Mann-Whitney U test), and significantly lower
than those of the patients on maintenance hemodialysis
(P < 0.0001, Mann-Whitney U test). The FGF-23 levels
of the patients on hemodialysis is extremely high even
those who have normal or slightly low serum phosphorus
levels.
Correlation between plasma FGF-23 levels
and other variables on maintenance hemodialysis
Factors affecting plasma FGF-23 levels were examined
by simple regression analysis. In the hemodialysis sub-
jects, FGF-23 level was significantly correlated positively
with inorganic phosphate (r = 0.544, P < 0.0001), intact
PTH (r = 0.446, P < 0.0001), corrected calcium (r =
0.355, P < 0.0001), and duration of hemodialysis (r =
0.260, P = 0.0010) (Fig. 1). FGF-23 level was also signif-
icantly and negatively correlated with age (r = −0.341,
P < 0.0001). FGF-23 did not correlate with systolic blood
pressure, hemoglobin, glucose, total cholesterol, or Kt/V
(integrated fractional clearance expressed per dialysis).
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Fig. 1. Simple regression analysis of factors correlating with plasma
fibroblast growth factor (FGF)-23 levels on maintenance hemodialysis.
Abbreviations are: FGF, fibroblast growth factor; PTH, parathyroid
hormone; cCa, corrected calcium.
Independent factors associated with plasma FGF-23
levels on maintenance hemodialysis
Factors independently associated with plasma FGF-
23 levels were examined using a multiple regression
model. Plasma FGF-23 level exhibited significant and
independent associations with duration of hemodialysis,
Imanishi et al: FGF-23 on hemodialysis 1945
Table 1. Multiple regression analysis of factors affecting plasma
fibroblast growth factor (FGF)-23 levels on maintenance hemodialysis
Variables b P
Age −0.006 0.9237
Duration of hemodialysis 0.126 0.0421
Kt/V 0.052 0.3870
Inorganic phosphate 0.494 <0.0001
Intact parathyroid hormone 0.289 <0.0001
Corrected-calcium 0.256 0.0001
R2 = 0.532 <0.0001
Abbreviations are: Kt/V, integrated fractional clearance expressed per dialysis;
R2, coefficient of determination. The table lists standard regression coefficients
(b values) and levels of significance.
corrected calcium, inorganic phosphate, and intact PTH
(Table 1). Age and Kt/V were not significant factors in
this model.
DISCUSSION
FGF-23 has phosphaturic activity, as shown by admin-
istration of recombinant FGF-23 to mice or transplan-
tation of FGF-23 expressing CHO cells into nude mice
[7]. Although the importance of FGF-23 is established
in the pathogenesis of phosphate wasting disorders, the
manner of regulation of its plasma level is still unknown.
Because of its hypophosphatemic effect, plasma FGF-23
level may be regulated or affected by plasma phosphate
level. In the present study, we examined this possibility
in uremic patients, who exhibit hyperphosphatemia. The
results revealed a significant and positive association be-
tween phosphate and FGF-23 levels independent of other
factors in patients on hemodialysis. This is the first report
showing increased FGF-23 concentrations in human sub-
jects with hyperphosphatemia. The positive correlation
between serum phosphate and plasma FGF-23 found in
this study, raises the possibility that serum phosphate may
be a regulator of plasma FGF-23 level.
In our preliminary study, we found that no correla-
tion was found between FGF-23 and serum phosphate
levels in nonuremic healthy subjects (data not shown).
Even though alimentary intake of phosphate is excessive,
surplus phosphate is excreted very quickly from the kid-
neys, and hyperphosphatemia is not usually observed in
healthy subjects. In uremic patients, excess phosphate in-
take directly causes hyperphosphatemia due to limitation
of phosphate removal by hemodialysis [8]. These facts
may explain why plasma FGF-23 level was correlated well
with serum phosphate level in patients on hemodialysis,
but not in normal subjects.
Administration of recombinant FGF-23 to mice did not
alter serum calcium or urinary calcium excretion in vivo
[7]; in addition, serum calcium and PTH levels are usu-
ally normal prior to phosphate supplementation treat-
ment in X-linked hypophosphatemia patients [9]. For
this reason, FGF-23 does not appear to be a regulator
of serum calcium or PTH. In the present study, how-
ever, plasma FGF-23 level also exhibited independent
associations with serum calcium and intact PTH levels,
suggesting that serum calcium and PTH are independent
regulators of FGF-23 in hemodialysis patients. The mech-
anisms of these types of regulation are still unknown, but
they could play a role in suppressing calcium x phosphate
product to prevent ectopic calcinosis.
In the present study, the duration of hemodialysis peri-
ods was independently associated with plasma FGF-23
level. Long-term exposure to abnormal phosphate-
calcium metabolism may affect FGF-23 levels. The lev-
els of plasma FGF-23 in the nondialyzed uremic patients
were significantly above the levels of healthy volunteers,
and significantly below the levels of the patients on main-
tenance hemodialysis. So, we considered that decreased
glomerular filtration rate (GFR) altered the level of the
FGF-23. Accumulation of FGF-23 may be present in re-
nal failure patient.
The method we employed in this study was to deter-
mine C-terminal FGF-23. To examine whether accumula-
tion of degraded fragments in our hemodialysis patients,
we also measured both intact and C-terminal FGF-23 in
another set of 25 patients on maintenance hemodialysis.
In the examination, a strong, significant correlation be-
tween these two assays was found (P < 0.0001, R = 0.873)
(data not shown). The ratios of intact/C-terminal FGF-
23 were similar between healthy controls and hemodial-
ysis patients (0.100+/−0.120 and 0.147+/−0.102 pg/RU,
respectively, P = 0.1822). These data indicate that both
intact and C-terminal FGF-23 significantly increased in
uremic patients and that accumulation of only degraded
fragments of FGF-23 seems to have a minor role in in-
creased FGF-23 levels in uremic patients.
Our observations provide the first evidence that FGF-
23 level is correlated with those of serum factors re-
lated to calcium-phosphate homeostasis. In conclusion,
serum phosphate, calcium, and intact PTH could be reg-
ulators of FGF-23 levels in uremic patients on mainte-
nance hemodialysis. Our results may provide new insights
into the pathophysiological effects of FGF-23 on calcium-
phosphate homeostasis.
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